Signal transduction and the u-PA/ u-PAR system

Fibrinolysis

Volumn 10, Issue 4, 1996, Pages 215-237

  Besser, D ^a,b,c   Verde, P ^a,b   Nagamine, Y ^a,c   Blasi, F ^a,b  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c Dipto Genet Biol Microrganismi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE; UROKINASE RECEPTOR;

CONFERENCE PAPER; FIBRINOLYSIS; GENETIC REGULATION; HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0029830493     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80018-X     Document Type: Review

References (253)

1. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987; 237: 1154-62.
2. Cohen S. Nobel lecture. Epidermal growth factor. Biosci Rep 1986; 6: 1017-28.
3. Groenen L C, Nice E C, Burgess A W. Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors 1994; 11: 235-57.
4. Chrysogelos S A, Dickson R B. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 1994; 29: 29-40.
5. Marshall C J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-85.
6. Aaronson S A. Growth factors and cancer. Science 1991; 254: 1146-53.
7. van der Geer P, Hunter T, Lindberg R A. Receptor protein-tyrosine kinase and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251-337.
8. Kaplan D R, Whitman M, Schaffhausen B et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 1987; 50: 1021-29.
9. s6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994; 370: 71-5.
10. Susa M, Vulevic D, Lane H A, Thomas G. Inhibition or down-regulation of protein kinase C attenuates late phase p70s6k activation induced by epidermal growth factor but not by platelet-derived growth factor or insulin. J Biol Chem 1992; 267: 6905-9.
11. Marshall C J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994; 4: 82-9.
12. Meisenhelder J, Suh P G, Rhee S G, Hunter T. Phospholipase C-γ is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro. Cell 1989; 57: 1109-22.
13. Ginty D D, Bonni A, Greenberg M E. Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Cell 1994; 77: 713-25.
14. Fu X-Y, Zhang J-J. Transcription factor p91 interacts with the epidermal growth factor receptor and mediates the activation of the c-fos gene promoter. Cell 1993; 74: 1135-45.
15. Johnson D E, Lee P L, Williams L T. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 1990; 10: 4728-36.
16. Hanks S K, Quinn A M. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol 1991; 200: 38-61.
17. Hanks S K, Quinn A M, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42-52.
18. Naldini L, Weidner K M, Vigna E et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the Met receptor. EMBOJ 1991; 10: 2867-78
19. Vigna E, Naldini L, Tamagnone L et al. Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. Cell Mol Biol 1994; 40: 597-604
20. Ip N Y, Stitt T N, Tapley P et al. Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron 1993; 10: 137-49.
21. Cunningham B C, Ultsch M, De Vos A M, Mulkerrin M G, Clauser K R, Wells J A. Dimerization of the extracellular domain of the human growth hormone by a single hormone molecule. Science 1991; 254: 821-5.
22. Hammacher A, Mellstrom K, Heldin C H, Westermark B. Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer. EMBO J 1989; 8: 2489-95.
23. Bardelli A, Maina F, Gout I et al. Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. Oncogene 1992; 7: 1973-8.
24. Daly R J. SH2 domain-containing signaling proteins in human breast cancer. Breast Cancer Res Treat 1995; 34: 85-92.
25. Erpel T, Courtneidge S A. Src family protein tyrosine kinases and cellular signal transduction pathways. Curr Opin Cell Biol 1995; 7: 176-82.
26. Pelicci G, Lanfrancone L, Grignani F et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992; 70: 93-104.
27. 7. Downward J. The GRB2/Sem-5 adaptor protein. FEES Lett 1994; 338: 113-7.
28. Ui M, Okada T, Hazeki K, Hazeki O. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem Sci 1995; 20: 303-7.
29. Parker P J. PI 3-kinase puts GTP on the Rac. Curr Biol 1995; 5: 577-9.
30. 2 hydrolysis and regulation of phospholipase C isozymes. Curr Opin Cell Biol 1995; 7: 183-9.
31. Panaretto B A. Aspects of growth factor signal transduction in the cell cytoplasm. J Cell Sci 1994; 107: 747-52.
32. Pawson T. SH2 and SH3 domains in signal transduction. Adv Cancer Res 1994; 64: 87-110.
33. Songyang Z, Shoelson S E, Chaudhuri M et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993; 72: 1-20.
34. van der Geer P, Pawson T. The PTB domain: a new protein module implicated in signal transduction. Trends Biochem Sci 1995; 20: 277-80.
35. De Meyts P, Wallach B, Christoffersen C T et al. The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. Horm Res 1994; 42: 152-69.
36. White M F, Livingston J N, Backer J M et al. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell 1988; 54: 641-9.
37. Keegan A D, Nelms K, White M F, Wang L-M, Pierce J H, Paul W E. An IL-4 receptor region containing an insulin receptor motif is important for IL-4 mediated IRS-1 phosphorylation and cell growth. Cell 1994; 76: 811-20.
38. Myers M G, Jr, Sun X J, White M F. The IRS-1 signaling system. Trends Biochem Sci 1994; 19: 289-93.
39. 1, transition. Proc Natl Acad Sci USA 1987; 6770-4.
40. McKeehan W L, Kan M. Heparan sulfate fibroblast growth factor receptor complex: structure- function relationships. Mol Reprod Dev 1994; 39: 69-82.
41. Reiland J, Rapraeger A C. Heparan sulfate proteoglycan and FGF receptor target basic FGF to different intracellular destinations. J Cell Sci 1993; 105: 1085-93.
42. Prochiantz A, Théodore L. Nuclear/growth factors. BioEssays 1995; 17: 39-44.
43. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson J D. Cell growth and differentiation. In: Molecular biology of the cell. New York: Garland Publishing Inc., 1994: 721-86.
44. Seger R, Krebs E G. The MAPK signaling cascade. FASEB J 1995; 9: 726-35.
45. Margolis B, Skolnik E Y. Activation of Ras by receptor tyrosine kinases. J Am Soc Nephrol 1994; 5: 1288-99.
46. Blumer K J, Johnson G L. Diversity in function and regulation of MAP kinase pathways. Trends Biochem Sci 1994; 19: 236-40.
47. Rozakis Adcock M, McGlade J, Mbamalu G et al. Association of the She and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 1992; 360: 689-92.
48. Feig L A. Guanine-nucleotide exchange factors: a family of positive regulators of Ras and related GTPases. Curr Opin Cell Biol 1994; 6: 204-11.
49. Burgering B M T, Bos J L. Regulation of Ras-mediated signalling: more than one way to skin a cat. Trends Biochem Sci 1995; 20: 18-22.
50. Gulbins E, Coggeshall M, Baier G, Katzav F, Burn P, Altaian A. Tyrosine kinase-stimulated guanine nucleotide exchange activity of Vav in T cell activation. Science 1993; 260: 822-5.
51. Margolis B, Hu P, Katzav S et al. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature 1992; 356: 71-4.
52. Errede B, Levin D E. A conserved kinase cascade for MAP kinase activation in yeast. Curr Opin Cell Biol 1993; 5: 254-60.
53. Kahan C, Seuwen K, Meloche S, Pouysségur J. Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. J Biol Chem 1992; 267: 13369-13375.
54. Berridge M J, Dupont G. Spatial and temporal signalling by calcium. Curr Opin Cell Biol 1994; 6: 267-74.
55. Berridge M J. Calcium signalling and cell proliferation. BioEssays 1995; 17: 491-500.
56. Dekker L V, Parker P J. Protein kinase C - a question of specificity. Trends Biochem Sci 1994; 19: 73-7.
57. Kolch W, Heidecker G, Kochs G et al. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993; 364: 249-52.
58. 2+-induced regulation of ion channel and MAP kinase functions. Nature 1995; 376: 737-45.
59. van Biesen T, Hawes B E, Luttrell D K et al. Receptor-tyrosinekinase- and Gβγ-mediated MAP kinase activation by a common signalling pathway. Nature 1995; 376: 781-4.
60. Touhara K, Hawes B E, van Biesen T, Lefkowitz R J. G protein βγ subunits stimulate phosphorylation of She adaptor protein. Proc Natl Acad Sci USA 1995; 92: 9284-7.
61. lck. Science 1994; 265: 853-5.
62. Rao V N, Reddy E S. Elk-1 proteins are phosphoproteins and activators of mitogen-activated protein kinase. Cancer Res 1993; 53: 3449-54.
63. Rao V N, Reddy E S. elk-1 proteins interact with MAP kinases. Oncogene 1994; 9: 1855-60.
64. TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 1992; 358: 414-7.
65. Karin M, Hunter T. Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 1995; 5: 747-57.
66. Karin M. Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. Curr Opin Cell Biol 1994; 6: 415-24.
67. Chen R H, Sarnecki C, Blenis J. Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol 1992; 12: 915-27.
68. Robbins D J, Zhen E, Cheng M, Xu S, Eben D, Cobb M H. MAP kinases ERK1 and ERK2: pleiotropic enzymes in a ubiquitous signaling network. Adv Cancer Res 1993; 60: 93-116.
69. Pulverer B J, Kyriakis J M, Avruch J, Nikolakaki E, Woodgett J R. Phosphorylation of c-jun mediated by MAP kinases. Nature 1991; 353: 670-4.
70. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993; 7: 2135-48.
71. Ueki K, Matsuda S, Tobe K et al. Feedback regulation of mitogen-activated protein kinase kinase kinase activity of c-Raf-1 by insulin and phorbol ester stimulation. J Biol Chem 1994; 269: 15756-61.
72. Stokoe D, Campbell D G, Nakielny S et al. MAPKAP kinase-2: a novel protein kinase activated by mitogen-activated protein kinase. EMBOJ 1992; 11: 3985-94.
73. Amick G D, Reddy S A, Damuni Z. Purification and properties of a protamine kinase from bovine kidney microsomes. Arch Biochem Biophys 1992; 297: 80-5.
74. Minshull J, Sun H, Tonks N K, Murray A W. A MAP kinase-dependent spindle assembly checkpoint in Xenopus egg extracts. Cell 1994; 79: 475-86.
75. Nigg E A. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. BioEssays 1995; 17: 471-80.
76. Boulton T G, Yancopoulos G D, Gregory JS et al. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 1990; 249: 64-7.
77. Minden A, Lin A, McMahon M et al. Differential activation of ERK and JNK mitogen activated protein kinases by Raf-1 and MEKK. Science 1994; 266: 1719-23.
78. Lin A, Minden A, Martinetto H et al. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 1995; 268: 286-90.
79. Deng T, Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 1994; 371: 171-5.
80. Nebreda A R. Inactivation of MAP kinases. Trends Biochem Sci 1995; 19: 1-2.
81. Sun H, Charles C H, Lau L F, Tonks N K. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993; 75: 487-93.
82. Liu Y, Gorospe M, Yang C, Holbrook N J. Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. J Biol Chem 1995; 270: 8377-80.
83. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-57.
84. Angel P, Imagawa M, Chiu R et al. Phorbol ester-inducible genes contain a common cis-element recognized by a TPA-modulated trans-acting factor. Cell 1987; 49: 729-39.
85. Lee W, Mitchell P J, Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 1987; 49: 741-52.
86. Rauscher F J, Voulalas P J, Franza R, Curran T. Fos and Jun bind cooperatively to the AP-1 site: reconstitution in vitro. Genes Dev 1988; 2: 1687-99.
87. Benbrook D M, Jones N C. Heterodimer formation between CREB and JUN proteins. Oncogene 1990; 5: 295-302.
88. Hai T W, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 1991; 88: 3720-3724.
89. van Dam H, Duyndam M, Rottier R et al. Heterodimer formation of c-Jun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus El A protein. EMBO J 1993; 12: 479-487.
90. Hagmeyer B M, Konig H, Herr I et al. Adenovirus El A negatively and positively modulates transcription of AP- 1 dependent genes by dimer-specific regulation of the DNA binding and transactivation activities of Jun. EMBOJ 1993; 12: 3559-72.
91. Pulverer B J, Hughes K, Franklin C C, Kraft A S, Leevers S J, Woodgett J R. Co-purification of mitogen activated protein kinase with phorbol ester induced cJun kinase activity in U937 leukaemia cells. Oncogene 1993; 8: 407-15.
92. Dérijard B, Hibi M, Wu I-H et al. JNK1 : a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76: 1025-37.
93. Papavassiliou A G, Treier M, Bohmann D. Intramolecular signal transduction in c-Jun. EMBO J 1995; 14: 2014-19.
94. Gille H, Strahl T, Shaw P E. Activation of the ternary complex factor Elk-1 by stress-activated protein kinases. Curr Biol 1995; 5: 1191-200.
95. Mechta F, Piette J, Hirai S I, Yaniv M. Stimulation of protein kinase C or protein kinase A mediated signal transduction pathways shows three modes of response among serum inducible genes. New Biol 1989; 1: 297-304.
96. Kovary K, Bravo R. Existence of different Fos/Jun complexes during the G0-to-G1 transition and during exponential growth in mouse fibroblasts: differential role of Fos proteins. Mol Cell Biol 1992; 12: 5015-23.
97. Treisman R. Journey to the surface of the cell: Fos regulation and the SRE. EMBO J 1995; 14: 4905-13.
98. Rozek D, Pfeifer G P. In vivo protein-DNA interactions at the c-jun promoter: preformed complexes mediate the UV response. Mol Cell Biol 1993; 13: 5490-99.
99. Konig H, Ponta H, Rahmsdorf H J, Herrlich P. Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo. EMBO J 1992; 11: 2241-46.
100. Rens-Domiano S, Hamm H E. Structural and functional relationships of heterotrimeric G-proteins. FASEB J 1995; 9: 1059-66.
101. Roesler W J, Vanderbark G R, Hanson R W. Cyclic AMP and the induction of eukaryotic gene expression. J Biol Chem 1988; 263: 9063-6.
102. Gonzalez G A, Yamamoto K K, Fischer W H et al. A cluster of phosphorylation sites on the cAMP-regulated nuclear factor CREB predicted by its sequence. Nature 1989; 337: 749-52.
103. Brindle P, Nakajima T, Montminy M R. Multiple protein kinase A-regulated events are required for transcriptional induction by cAMP. Proc Natl Acad Sci USA 1995; 92: 10521-5.
104. Lee C Q, Yun Y, Hoeffler J P, Habener J F. Cyclic-AMP-responsive transcriptional activation involves interdependent phosphorylation subdomains. EMBO J 1990; 9: 4455-65.
105. Delmas V, Molina C A, Lalli E et al. Complexity and versatility of the transcriptional response to cAMP. Rev Physiol Biochem Pharmacol 1994; 124: 1-28.
106. Papavassiliou A G. The CREB/ATF family of transcription factors: modulation by reversible phosphorylation. Anticancer Res 1994; 14: 1801-05.
107. Gonzalez G A, Montminy M R. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989; 59: 675-80.
108. Gonzalez G A, Menzel P, Leonard J, Fischer W H, Montminy M R. Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. Mol Cell Biol 1991; 11: 1306-1312.
109. Chrivia J C, Kwok R P, Lamb N, Hagiwara M, Montminy M R, Goodman R H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993; 365: 855-9.
110. Kwok R P, Lundblad J R, Chrivia J C et al. Nuclear protein CBP is a coactivator for the transcription factor CREB (see comments). Nature 1994; 370: 223-6.
111. Hagiwara M, Alberts A, Brindle P et al. Transcriptional attenuation following cAMP induction requires PP-1- mediated dephosphorylation of CREB. Cell 1992; 70: 105-13.
112. Nichols M, Weih F, Schmid W et al. Phosphorylation of CREB affects its binding to high and low affinity sites: implications for cAMP induced gene transcription. EMBO J 1992: 11: 3337-46.
113. Laoide B M, Foulkes N S, Schlotter F, Sassone-Corsi P. The functional versatility of CREM is determined by its modular structure. EMBO J 1993; 12: 1179-91.
114. de Groot R P, den Hertog J, Vandenheede J R, Goris J, Sassone-Corsi P. Multiple and cooperative phosphorylation events regulate the CREM activator function. EMBO J 1993; 12: 3903-11.
115. Hai T W, Liu F, Coukos W J, Green M R. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DA binding heterodimers. Genes Dev 1989; 3: 2083-90.
116. Rehfuss R P, Walton K M, Loriaux M M, Goodman R H. The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase. J Biol Chem 1991; 266: 18431-4.
117. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 1995; 14: 1798-811.
118. Liu F, Green M R. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1 a protein. Cell 1990; 61: 1217-24.
119. Arany Z, Sellers W R, Livingston D M, Eckner R. El A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994; 77: 799-800.
120. Janaswami P M, Kalvakolanu D V, Zhang Y, Sen G C. Transcriptional repression of interleukin-6 gene by adenoviral El A proteins. J Biol Chem 1992; 267: 24886-91.
121. Kim S-J, Wagner S, Liu F, O'Reilly M A, Robbins P D, Green M R. Retinoblastoma gene product activates expression of the human TGF-β2 gene through transcription factor ATF-2. Nature 1992; 358: 331-4.
122. Masquilier D, Sassone-Corsi P. Transcriptional cross-talk:
123. nuclear factors CREM and CREB bind to AP-1 sites and inhibit activation by Jun. J Biol Chem 1992; 267: 22460-6.
124. Sassone-Corsi P, Ransone LJ, Verma IM. Cross-talk in signal transduction: TPA-inducible factor Jun/AP1 activates cAMP responsive enhancer elements. Oncogene 1990; 5: 427-31.
125. Bohm M, Moellman G, Cheng E et al. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 1995; 6: 291-302.
126. Macleod K, Leprince D, Stehelin D. The etegene family. Trends Biochem Sci 1992; 17: 251-6.
127. Wasylyk B, Hahn S L, Giovane A. The Ets family of transcription factors (published erratum appears in Eur J Biochem 1993 Aug 1; 215(3):907). Eur J Biochem 1993; 211: 7-18.
128. Leprince D, Gégonne A, Coll J et al. A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature 1983; 306: 395-7.
129. Seth A, Watson D K, Blair D G, Papas T S. c-ets-2 protooncogene has mitogenic and oncogenic activity. Proc Natl Acad Sci USA 1989; 86: 7833-7.
130. Janknecht R, Nordheim A. Gene regulation by Ets proteins. Biochim Biophys Acta 1993; 1155: 346-56.
131. Coffer P, de Jonge M, Mettouchi A, Binétruy B, Ghysdael J, Kruijer W. junB promoter regulation: Ras mediated transactivation by c-Ets-1 and c-Ets-2. Oncogene 1994; 9: 911-21.
132. Dittmer J, Gegonne A, Gitlin S D, Ghysdael J, Brady J N. Regulation of parathyroid hormone-related protein (PTHrP) gene expression. Sp1 binds through an inverted CACCC motif and regulates promoter activity in cooperation with Etsl. J Biol Chem 1994; 269: 21428-34.
133. Espinas M L, Roux J, Ghysdael J, Fielet R, Grange T. Participation of Ets transcription factors in the glucocorticoid response of the rat tyrosine aminotransferase gene. Mol Cell Biol 1994; 14: 4116-25.
134. Roussel M F, Davis J N, Cleveland J L, Ghysdael J, Hiebert S W. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene 1994; 9: 405-15.
135. Lim F, Kraut N, Frampton J, Graf T. DNA binding by c-Ets-1, but not v-Ets, is repressed by an intramolecular mechanism. EMBOJ 1992; 11: 643-52.
136. Frampton J, Leutz A, Gibson T J, Graf T. DNA-binding domain ancestry (letter). Nature 1989; 342: 134.
137. Wasylyk C, Kerckaert J-P, Wasylyk B. A novel modulator domain of Ets transcription factors. Genes Dev 1992; 6: 965-74.
138. Hagman J, Grosschedl R. An inhibitory carboxyl-terminal domain in Ets-1 and Ets-2 mediates differential binding of ETS family factors to promoter sequences of the mb-1 gene. Proc Natl Acad Sci USA 1992; 89: 8889-93.
139. Brown T A, McKnight S L. Specificities of protein-protein and protein-DNA interaction of GABP alpha and two newly defined ets-related proteins. Genes Dev 1992; 6: 2502-12.
140. Treisman R. The serum response element. Trends Biochem Sci 1992; 17: 423-6.
141. Dalton S, Treisman R. Characterization of SAP-1, a protein recruited by serum response factor to the c-fos serum response element. Cell 1992; 68: 597-612.
142. Thompson C C, Brown T A, McKnight S L. Convergence of Ets-and notch-related structural motifs in a heteromeric DNA binding complex (see comments). Science 1991; 253: 762-8.
143. Wasylyk B, Wasylyk C, Flores P, Begue A, Leprince D, Stehelin D. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature 1990; 346: 191-3.
144. Gégonne A, Bosselut R, Bailly R-A, Ghysdael J. Synergistic activation of the HTLV1 LTR Ets-responsive region by transcription factors Ets1 and Sp1. EMBO J 1993; 12: 1169-78.
145. Kortenjann M, Thomae O, Shaw P E. Inhibition oiv-raf-dependent c-fos expression and transformation by a kinase defective mutant of the mitogen-activated protein kinase Erk2. Mol Cell Biol 1994; 14: 4815-24.
146. Gille H, Kortenjann M, Thomae O et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995; 14: 951-62.
147. Janknecht R, Ernst W H, Pingoud V, Nordheim A. Activation of ternary complex factor Elk-1 by MAP kinases. EMBO J 1993; 12: 5097-104.
148. Marais R, Wynne J, Treisman R. The SRF accessory protein ELK-1 contains a growth factor regulated transcription domain. Cell 1993; 73: 381-93.
149. Shaw P E, Frasch S, Nordheim A. Repression of c-fos transcription is mediated through p67SRF bound to the SRE. EMBO J 1989; 8: 2567-74.
150. Zinck R, Hipskind R A, Pingoud V, Nordheim A. c-fos transcriptional activation and repression correlate temporally with the phosphorylation status of TCF. EMBO J 1993; 12: 2377-87.
151. Brunner D, Dücker K, Oellers N, Hafen E, Scholz H, Klambt C. The ETS domain protein pointed-P2 is a target of MAP kinase in the sevenless signal transduction pathway. Nature 1994; 370: 386-9.
152. O Neill E M, Rebay I, Tjian R, Rubin G M. The activities of two Ets-related transcription factors required for Drosophila eye development are modulated by the Ras/MAPK pathway. Cell 1994; 78: 137-47.
153. Beato M. Gene regulation by steroid hormones. Cell 1994; 56: 335-44.
154. Ray A, Prefontaine K E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91: 752-6.
155. Miner J N, Yamamoto K R. Regulatory crosstalk at composite response elements. Trends Biochem Sci 1991; 16: 423-6.
156. Schule R, Evans R M. Cross-coupling of signal transduction pathways: zinc finger meets leucine zipper. Trends Genet 1991; 7: 377-81.
157. Saatcioglu F, Claret F X, Karin M. Negative transcriptional regulation by nuclear receptors. Semin Cancer Biol 1994; 5: 347-59.
158. Miyamoto S, Verma I M. Rel/NF-kappa B/I kappa B story. Adv Cancer Res 1995; 66: 255-92.
159. Amati B, Land H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev 1994; 4: 102-8.
160. Atchley W R, Fitch W M. Myc and Max: Molecular evolution of a family of proto-oncogene products and their dimerization partner. Proc Natl Acad Sci USA 1995; 92: 10217-21.
161. Chin L, Schreiber-Agus N, Pellicer I et al. Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci USA 1995; 92: 8488-92.
162. Ihle J N, Kerr I M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995; 11: 69-74.
163. Gutman A, Wasylyk B. Nuclear targets for transcription regulation by oncogenes. Trends Genet 1991; 7: 49-54.
164. von der Ahe D, Pearson D, Nakagawa J, Rajput B, Nagamine Y. Multiple nuclear factors interact with promoter sequences of the urokinase-type plasminogen activator gene. Nucleic Acids Res 1988; 16: 7527-44.
165. Cassady A I, Stacey K J, Nimmo K A et al. Constitutive expression of the urokinase plasminogen activator gene in murine Raw264 macrophages involves distal and 5′ non-coding sequences that are conserved between mouse and pig. Nucleic Acids Res 1991; 19: 6839-47.
166. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F. The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res 1985; 13: 2759-71.
167. Nagamine Y, Lee J S, Menoud P-A, Nanbu R. Structure and function of the urokinase-type plasminogen activator gene. In: Glas-Greenwalt P, ed. Fibrinolysis in disease. Boca Raton, Florida, USA: CRC Press Inc. 1995: 10-20.
168. Nerlov C, Rorth P, Blasi F, Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991; 6: 1583-92.
169. Besser D, Urich M, Sakaue M, Messetschmitt A, Ballmer-Hofer K, Nagamine Y. Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen. Oncogene 1995; 11: 2383-91.
170. Besser D, Presta M, Nagamine Y. Elucidation of a signaling pathway induced by FGF-2 leading to u-PA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ 1995; 6: 1009-17.
171. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem 1995; 270: 23007-12.
172. Lengyel E, Singh B, Gum R et al. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene 1995; 11: 2639-48.
173. Stacey K J, Fowles L F, Coman M S, Ostrowski M C, Hume D A. Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. Mol Cell Biol 1995; 15: 3430-41
174. Rorth P, Nerlov C, Blasi F, Johnsen M. Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester. Nucleic Acids Res 1990; 18: 5009-17.
175. 1 cells. Nucleic Acids Res 1993; 21: 3365-72.
176. Lee J S, Favre B, Hemmings B A, Kiefer B, Nagamine Y. Okadaic acid-dependent induction of the urokinase-type plasminogen activator gene associated with stabilization and autoregulation of c-Jun. J Biol Chem 1994; 269: 2887-94.
177. Nerlov C, De Cesare D, Pergola F et al. A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 1992; 11: 4573-82.
178. Berthelsen J, Vandekerchove J, Blasi F. Purification and characterization of UEF3, a novel factor involved in the regulation of the urokinase and other AP-1 controlled promoters. J Biol Chem 1996; 271: 3822-30.
179. De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. Heterodimerization of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 1995; 11: 365-76.
180. Lanz R B, Wieland S, Hug M, Rusconi S. A transcriptional repressor obtained by alternative translation of a trinucleotide repeat. Nucleic Acids Res 1995; 23; 138-45.
181. Nagamine Y, Sudol M, Reich E. Hormonal regulation of plasminogen activator mRNA production in porcine kidney cells. Cell 1983; 32: 1181-90.
182. Degen J L, Estensen R D, Nagamine Y, Reich E. Induction and desensitization of plasminogen activator gene expression by tumor promoters. J Biol Chem 1985; 260: 12426-33.
183. Tranque P, Robbins R, Naftolin F, Andrade Gordon P. Regulation of plasminogen activators and type-1 plasminogen activator inhibitor by cyclic AMP and phorbol ester in rat astrocytes. Glia 1992; 6: 163-71.
184. Nonaka T, Matsumoto H, Shimada W et al. Effect of cyclic AMP on urokinase-type plasminogen activator receptor and fibrinolytic factors in a human osteoblast-like cell line. Biochim Biophys Acta 1995; 1266: 50-6.
185. Clegg C H, Abrahamsen M S, Degen J L, Morris D R, McKnight G S. Cyclic AMP-dependent protein kinase controls basal gene activity and steroidogenesis in Y1 adrenal tumor cells. Biochemistry 1992; 31: 3720-26.
186. Rossi P, Grimaldi P, Blasi F, Geremia R, Verde P. Follicle-stimulating hormone and cyclic AMP induce transcription from the human urokinase promoter in primary cultures of mouse Sertoli cells. Mol Endocrinol 1990; 4: 940-6.
187. Holmberg M, Leonardson G, Ny T. The species-specific differences in the cAMP regulation of the tissue-type plasminogen activator gene between rat, mouse and human is caused by a one-nucleotide substitution in the cAMP-responsive element of the promoters. Eur J Biochem 1995; 231: 466-74.
188. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 1987; 51: 251-60.
189. Lee J S, Catanzariti L, Hemmings B A, Kiefer B, Nagamine Y. Activation of cAMP-dependent protein kinase alters the chromatin structure of the urokinase-type plasminogen activator gene promoter. Nucleic Acids Res 1994; 22: 569-75.
190. Menoud P-A, Matthies R, Hofsteenge J, Nagamine Y. Purification and cDNA cloning of a transcription factor which functionally cooperates within a cAMP regulatory unit in the porcine u-PA gene. Nucleic Acids Res 1993; 21: 1845-52.
191. Marksitzer R, Stief A, Menoud P-A, Nagamine Y. Role of LFB3 in cell-specific cAMP induction of the urokinase-type plasminogen activator gene. J Biol Chem 1995; 270:
192. De Simone V, Cortese R. Transcriptional regulation of liverspecific gene expression. Curr Opin Cell Biol 1992; 3: 960-5.
193. Hansen S K, Nerlov C, Zabel U et al. A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 1992; 11: 205-13.
194. Novak U, Cocks BG, Hamilton J A. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids Res 1991; 19: 3389-93.
195. Verde P, Boast S, Franze A, Robbiati F, Blasi F. An upstream enhancer and a negative element in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 1988; 16: 10699-716.
196. Cannio R, Rennie P S, Blasi F. A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene. Nucleic Acids Res 1991; 19: 2303-8.
197. von der Ahe D, Pearson D, Nagamine Y. Macromolecular interaction on a cAMP responsive region in the urokinase-type plasminogen activator gene: a role
198. Altus M S, Pearson D, Horiuchi A, Nagamine Y. Inhibition of protein synthesis in LLC-PK1 cells increases calcitonin-induced plasminogen-activator gene transcription and mRNA stability. Biochem J 1987; 242: 387-92.
199. Nagamine Y, Ziegler A. Okadaic acid induction of the urokinase-type plasminogen activator gene occurs independently of cAMP-dependent protein kinase and protein kinase C and is sensitive to protein synthesis inhibition. EMBO J 1991; 10: 117-22.
200. Pearson D, Altus M S, Horiuchi A, Nagamine Y. Dexamethasone coordinately inhibits plasminogen activator gene expression and enzyme activity in porcine kidney cells. Biochem Biophys Res Commun 1987; 143: 329-36.
201. Medcalf R L, Richards R I, Crawford R J, Hamilton J A. Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids. EMBO J 1986; 5: 2217-22.
202. Vitti G F, Hamilton J A. Modulation of urokinase-type plasminogen activator messenger RNA levels in human synovial fibroblasts by interleukin-1, retinoic acid, and a glucocorticoid. Arthritis Rheum 1988; 31: 1046-51.
203. Ploug M, Ellis V. Structure-function relationship in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom a-neurotoxins. FEBS Lett 1994; 349: 163-8.
204. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Danø K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem. 1991; 266: 7842-7.
205. Ploug M, Ellis V, Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphtalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1993; 33: 8991-7.
206. Riittinen L, Limongi P, Crippa M P et al. In vivo expression of functional mutant urokinase receptor lacking domain D2 or domain D3. FEES Lett 1996; 381: 1-6.
207. Ellis V, Scully M F, Kakkar V V. Plasminogen activation initiated by single-chain urokinase plasminogen activator: potentiation by U937 cells. J Biol Chem 1989; 264: 2185-8.
208. Stephens R W, Pöllänen J, Tapiovaara H et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-95.
209. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin D B. Characterization of the activation of latent TFG-b by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self regulating system. J Cell Biol 1990; 111: 757-74.
210. Odekon L E, Blasi F, Rifkin D B. A requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 1994; 158: 396-407.
211. Naldini L, Tamagnone L, Vigna et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992; 11: 4825-33.
212. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio P M. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 1995; 270: 603-11.
213. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15: 1572-82.
214. Bohuslav J, Horejsi V, Hansmann C et al. Urokinase plasminogen activator receptor β2-type integrins and src-kinases within a single receptor complex of human monocytes. J Exp Med 1995; 181: 1381-90.
215. Waltz D A, Chapman H A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 32380-8.
216. Wei Y, Waltz D A, Rao N, Drummond R J, Rosenberg S, Chapman H A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-8.
217. Kanse S M, Kost C, Wilhelm O G, Andreasen P A, Preissner K T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224: (in press).
218. Gudewicz P W, Gilboa N. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem. Biophys Res Commun 1987; 147: 1176-81.
219. Fibbi G, Ziehe M, Morbidelli L, Magnelli L, Del Rosso M. Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 1988; 179: 385-95.
220. Del Rosso M, Fibbi G, Dini G et al. J Invest Dermatol 1990; 94: 310-6.
221. Del Rosso M, Anichini E, Pedersen N et al. Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem Biophys Res. Commun 1993; 190: 347-52.
222. Dumler I, Petri T, Schleuning W D. Interaction of the urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett 1993; 322: 37-40.
223. Busso N, Masur S K, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994; 126: 259-70.
224. Gyetko M R, Todd R F, Wilkinson C C, Sitrian R G. The urokinase receptor is required for human monocyte chemotaxis in vivo. J Clin Invest 1994; 93: 1380-7.
225. Nykjær A, Møller B, Todd R F I et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 1994; 152: 505-16.
226. Picone R, Kajtaniak E L, Nielsen L S et al. Regulation of urokinase receptors in in monocyte-like U937 cells by phorbol ester phorbol-myristate-acetate. J Cell Biol 1989; 108: 693-702.
227. Waltz D S, Sailor L Z, Chapman H A. Cytokines induce urokinase-dependent adhesion of human myeloid cells: a regulatory role for plasminogen activator inhibitors. J Clin Invest 1993; 91: 1541-52.
228. Rao N K, Shi G-P, Chapman H A. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest 1995; 96: 465-74.
229. Nusrat A R, Chapman H A. An autocrine role for urokinase in phorbol-ester-mediated differentiation of myeloid cell lines. J Clin Invest 1991; 87: 1091-7.
230. Preissner K T, Anders E, Grulich-Henn J, Müller-Berghaus G. Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S-protein-thrombin-antithrombin III complex. Blood 1998; 71: 1581-9.
231. Mimuro J, Loskutoff D J. Purification of a protein from human plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 1989; 264: 936-9.
232. Moser T L, Enghild J J, Pizzo S V, Stack S M. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA dependent adhesion of U-937 cells. Biochem J 1995; 307: 867-73.
233. Xue W, Kindzelskii A L, Todd R F, Petty H R. Physical association of complement receptor type 3 and urokinase type plasminogen activator receptor in neutrophil membranes. J Immunol 1994; 152: 4630-40.
234. Kindzelskii A L, Laska Z O, Todd II R F, Petty H R. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (αMβ2 CD1 1b/CD18) during neutrophil polarization. J Immunol 1996; 156: 297-309.
235. Dustin M L, Springer T. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol 1991; 9: 27-66.
236. Pöllänen J, Saksela O, Salonen E-M et al. Distinct localization of urokinase-type plasminogen activator and its type-1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987; 104: 1085-96.
237. Myöhänen H T, Stephens R W, Hedman K et al. Distribution and lateral mobility of the urokinase receptor complex at the cell surface. J Histochem Cytochem 1993; 41: 1291-301.
238. Cubellis M V, Andreasen P A, Ragno P, Mayer M, Danø K, Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Nad Acad Sci USA 1989; 86: 4828-32.
239. Cubellis M V, Wun T-C, Blasi F. Receptor-mediated internalization and degradation of urokinase-PAI-1 complex in human U937 cells. EMBO J, 1990; 9: 1079-85.
240. Conese M, Olson D, Blasi F. Protease Nexin-1:urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha-2 macroglobulin receptor. J Biol Chem, 1994; 269: 17886-92.
241. Nykjær A, Petersen C M, Møller B et al. Purified alpha-2 macroglobulin receptor/LDL receptor related protein binds urokinase plasminogen activator type-1 complex. Evidence that alpha-2 macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992; 267: 14543-6.
242. Conese M, Nykjær A, Christensen EI et al. Alpha-2 macroglobulin receptor-dependent internalization of the urokinase receptor. J Cell Biol 1995; 131: 1609-22.
243. Ciambrone G L, McKeown-Longo P J et al. Plasminogen activator type-1 stabilizes vitronectin-dependent adhesion in HT1080 cells. J Cell Biol 1990; 111: 2183-2195.
244. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type-1 inhibitor in breast cancer. Semin Thromb Hemost 1991; 17: 303-12.
245. Blasi F. Urokinase and its receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 1993; 15: 105-11.
246. Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 1994; 15: 25-9.
247. Kirchheimer J C, Wojta J, Christ G, Binder B R. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1987; 1: 125-8.
248. He C J, Rebibou J M, Peraldi M N, Meulders Q, Rondeau E. Growth factor-like effect of urokinase type plasminogen activator in human renal cells. Biochem Biophys Res Commun 1991; 176: 1408-16.
249. Rabbani S A, Desjardins J, Bell A W et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173: 1058-64.
250. Rabbani S A, Mazar A P, Bernier S M et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992; 267: 14151-6.
251. Kaplan K B, Swedlow J R, Morgan D O, Varmus H E. c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev 1995; 9: 1505-17.
252. Høyer-Hansen G, Rønne E, Solberg H et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224-9.
253. Solberg H, Rømer J, Brünner N et al. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 1994; 58: 877-81.